Home About us Contact
|
Home About us Contact | ||
|
|
||
Therapeutic Products (therapeutic + products)
Selected AbstractsGuideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disordersHAEMOPHILIA, Issue 4 2008A UNITED KINGDOM HAEMOPHILIA CENTER DOCTORS' ORGANISATION (UKHCDO) GUIDELINE APPROVED BY THE BRITISH COMMITTEE FOR STANDARDS IN HAEMATOLOGY Summary., Evidence-based guidelines are presented on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. They include details of therapeutic products available in the UK and they update and replace previous United Kingdom Haemophilia Centre Doctors' Organisation guidelines. [source] Safety and supply of haemophilia products: worldwide perspectivesHAEMOPHILIA, Issue 4 2004A. Farrugia Summary., The survival and well-being of people with haemophilia depends on the supply of safe therapeutic products. Safety and supply are entirely intertwined principles; in the absence of adequate amounts of coagulation products, safety measures may be compromised in order to enhance supply, leading to risks which may result in morbidity and mortality. As haemophilia therapy has emerged through the development of blood transfusion and plasma fractionation, the safety of the blood supply in general has had a strong effect on haemophilia care. Despite the gradual detachment of haemophilia care from blood transfusion through the use of recombinant products, the majority of the world's population with haemophilia in the developing world will be reliant on blood products for the foreseeable future. It is, therefore, important to continue efforts for a safe and sufficient blood supply worldwide. As such a blood supply develops, possibly in tandem with an independent plasma fractionation industry, the level of haemophilia care should improve with the gradual introduction of concentrates for the ultimate goal of covering all aspects of care. Constant vigilance for the threat of blood-borne pathogens should be linked to considerations of how these products are to be manufactured. This should be governed entirely by considerations of safety and pharmaceutical competence. Of equal importance is a governmental capacity to oversee the entry and maintenance of these products on the market. While it is not possible for all countries to have a regulatory authority of the same status as that of the developed countries, it is perfectly feasible to develop a set of basic principles which allow an assessment of basic product safety, quality and efficacy to be made. [source] Management of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' OrganizationHAEMOPHILIA, Issue 3 2004K. J. Pasi Summary., von Willebrand disease (VWD) is the commonest inherited bleeding disorder. The aim of therapy for VWD is to correct the two defects of haemostasis in this disorder, impaired primary haemostasis because of defective platelet adhesion and aggregation and impaired coagulation as a result of low levels of factor VIII. The objective of this guideline is to inform individuals making choices about the treatment and management of VWD including the use of therapeutic products. This is the second edition of this UK Haemophilia Centre Doctors' Organization (UKHCDO) guideline and supersedes the previous edition which was published in 1994. [source] Haemophilia 2002: emerging risks of treatmentHAEMOPHILIA, Issue 3 2002B. L. EVATT Haemophilia care and treatment products have greatly improved over the past 2 decades. Transitions in treatment produced by these changes were accompanied by the emergence of unexpected risks and new complications. In order to provide the best comprehensive care to patients with haemophilia, healthcare providers periodically need to re-evaluate and adjust their management and therapeutic products to prevent or minimize the effects produced by the emerging issues. For example, reducing the effects of infectious agents remains the highest priority for the haemophilia community because of the high level of morbidity and mortality that has resulted from earlier therapeutic agents. In many countries, the goal has been to achieve absolute zero risk for infectious agents. In some instances, the screening procedures to achieve these goals reduced the availability of plasma needed for manufactured derivatives and produced another emerging risk, shortages of clotting factor preparations. Similarly, better diagnostic methods identified other potential agents that were not inactivated by current technology. Likewise, immune tolerance regimens and the prophylactic management of haemophilia introduced different therapeutic delivery systems with their own risks. The drugs used to manage diseases such as human immunodeficiency virus (HIV), which were transmitted by products manufactured before mid-1980, create their own set of risks for this community. Topical emerging risks of treatment, including variant Creutzfeldt,Jakob disease, an assessment of its risks and impact, the complications of using indwelling catheters, and the role of protease inhibitors used to treat HIV may have on bleeding complications of haemophilia are discussed. [source] Non-invasive detection of the metabolic burden on recombinant microorganisms during fermentation processes,JOURNAL OF CHEMICAL TECHNOLOGY & BIOTECHNOLOGY, Issue 8 2001Th Bachinger Abstract Heterologous protein production is an important source of therapeutic products. Optimisation of such bioprocesses by adjustment of the expression rate of the heterologous protein to the biosynthetic capacity of the cell metabolism would benefit from an online method for monitoring the metabolic burden. In this study we evaluated the use of a chemical multi-sensor array for this purpose. Fermentations with a recombinant Escherichia coli strain expressing human superoxide dismutase (rhSOD) were monitored by the sensor array. The results of isopropyl-thiogalactopyranoside (IPTG)-induced expression were compared with fermentations with a plasmid-free strain. The overproduction of rhSOD, imposing a high metabolic burden on the plasmid-carrying cells, was distinctly and reproducibly observed by the multi-sensor array. The potential of this non-invasive method of non-specific metabolic burden monitoring is demonstrated by the results of the study. © 2001 Society of Chemical Industry [source] Model competencies in regulatory therapeutic product assessment: Health Canada's good review guiding principles as a reviewing community's code of intellectual conduct,,§¶PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, Issue 8 2007Robyn R. Lim PhD Abstract Purpose This article describes some work from the Therapeutic Products Directorate of Health Canada regarding Good Review Practices (GRP). Methods and Results Background information is provided on the Therapeutic Products Directorate (TPD) and its regulatory activities regarding drug and medical device assessment in both the pre- and post-market setting. The TPD Good Review Guiding Principles (GRGP) are described which include a Definition of a Good Therapeutic Product Regulatory Review, Ten Hallmarks of a Good Therapeutic Product Regulatory Review and Ten Precepts. Analysis of the guiding principles discusses possible linkages between the guiding principles and intellectual virtues. Conclusions Through this analysis an hypothesis is developed that the guiding principles outline a code of intellectual conduct for Health Canada's reviewers of evidence for efficacy, safety, manufacturing quality and benefit-risk regarding therapeutic products. Opportunities to advance therapeutic product regulatory review as a scientific discipline in its own right and to acknowledge that these reviewers constitute a specific community of practice are discussed. Integration of intellectual and ethical approaches across therapeutic product review sectors is also suggested. Copyright © 2007 Crown in the right of Canada. Published by John Wiley & Sons, Ltd. [source] Benefit assessment of therapeutic products: the Centers for Education and Research on Therapeutics,PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, Issue 1 2007Robert M. Califf MD Abstract The ability to manage risk depends critically on an understanding of the degree to which a known risk is balanced by the probability of a clinical benefit. Despite the massive emphasis on risk and risk management in the past few years and the long-term focus on defining benefit in the regulatory system, considerable uncertainty remains about the methods of defining benefit and how to operationalize this knowledge. In this ,think tank,' part of a larger series on risk management, issues were divided into those that can be identified before a study is initiated, those that commonly arise after a study is completed, biomarkers and surrogates, use of benefit findings in defining quality and performance indicators, implementation of findings into health systems and formularies, and methods of comparative trials. Key categories for the establishment of a research agenda to fill in gaps in our understanding of assessing benefit were developed by the group. Copyright © 2006 John Wiley & Sons, Ltd. [source] Strategies for developing design spaces for viral clearance by anion exchange chromatography during monoclonal antibody productionBIOTECHNOLOGY PROGRESS, Issue 3 2010Daniel M. Strauss Abstract The quality-by-design (QbD) regulatory initiative promotes the development of process design spaces describing the multidimensional effects and interactions of process variables on critical quality attributes of therapeutic products. However, because of the complex nature of production processes, strategies must be devised to provide for design space development with reasonable allocation of resources while maintaining highly dependable results. Here, we discuss strategies for the determination of design spaces for viral clearance by anion exchange chromatography (AEX) during purification of monoclonal antibodies. We developed a risk assessment for AEX using a formalized method and applying previous knowledge of the effects of certain variables and the mechanism of action for virus removal by this process. We then use design-of-experiments (DOE) concepts to perform a highly fractionated factorial experiment and show that varying many process parameters simultaneously over wide ranges does not affect the ability of the AEX process to remove endogenous retrovirus-like particles from CHO-cell derived feedstocks. Finally, we performed a full factorial design and observed that a high degree of viral clearance was obtained for three different model viruses when the most significant process parameters were varied over ranges relevant to typical manufacturing processes. These experiments indicate the robust nature of viral clearance by the AEX process as well as the design space where removal of viral impurities and contaminants can be assured. In addition, the concepts and methodology presented here provides a general approach for the development of design spaces to assure that quality of biotherapeutic products is maintained. © 2010 American Institute of Chemical Engineers Biotechnol. Prog., 2010 [source] | ||||||||||